JEFFREY E GERSHENWALD to Neoadjuvant Therapy
This is a "connection" page, showing publications JEFFREY E GERSHENWALD has written about Neoadjuvant Therapy.
Connection Strength
0.444
-
Top Melanoma Articles from 2021 to Inform Your Cancer Practice. Ann Surg Oncol. 2023 Oct; 30(11):6325-6331.
Score: 0.085
-
Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022 11; 611(7934):155-160.
Score: 0.081
-
Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. J Natl Cancer Inst. 2020 09 01; 112(9):875-885.
Score: 0.069
-
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019 07; 20(7):e378-e389.
Score: 0.064
-
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
Score: 0.061
-
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol. 2022 Jun; 29(6):3694-3708.
Score: 0.019
-
The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. J Transl Med. 2021 04 07; 19(1):142.
Score: 0.018
-
Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Ann Oncol. 2020 11; 31(11):1569-1579.
Score: 0.017
-
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018 08 01; 29(8):1861-1868.
Score: 0.015
-
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
Score: 0.014